Skip to main content
. Author manuscript; available in PMC: 2010 Oct 6.
Published in final edited form as: Mol Cancer Ther. 2009 Oct 6;8(10):2926–2936. doi: 10.1158/1535-7163.MCT-08-1223

Figure 4.

Figure 4

Comparison of model simulations to in vitrosimulations designed to study the effect of BL193 on capillary formation. A, B, C, In capillary sprouting assays described in [14], HDMECs were cultured on type I collagen in the presence of 50 ng per ml VEGF. Starting on day 5, BL193 was administered in increasing doses from 0.05 µM (A), 0.5 µM (B), and 5 µM (C), and the number of sprouts counted. Numerical simulations of our model are seen to be in good agreement with experimental data, thus providing a validation for it. D Intra-cellular Bcl-2, Bad and BL193 levels are tracked with time, as 0.05 µM BL193 therapy is administered. Starting on day 5, BL193 levels within a cell begin to increase, causing a decrease in amounts of unbound Bcl-2 protein, and a corresponding increase in unbound Bad protein.